{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,6]],"date-time":"2026-01-06T13:22:37Z","timestamp":1767705757423},"reference-count":13,"publisher":"American Society of Hematology","issue":"4","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2008,2,15]]},"abstract":"<jats:p>Alemtuzumab is an immunosuppressive antibody that depletes normal T cells and B cells. Prophylaxis for herpes virus and Pneumocystis carinii is standard with this agent. Approximately 20% to 25% of patients will experience cytomegalovirus (CMV) reactivation. We conducted a randomized trial wherein patients being treated with an alemtuzumab-containing regimen received prophylaxis with either valaciclovir 500 mg orally daily or valganciclovir 450 mg orally twice daily. The study design planned to enroll 128 patients, but stopping rules for early termination were met. Forty patients were evaluable. Median age was 58 years (range, 25\u201383 years); median number of prior therapies was 2 (range, 0\u201310). Diagnoses included chronic lymphocytic leukemia (29), T-cell prolymphocytic leukemia (3), hairy cell leukemia (1), adult T-cell leukemia\/lymphoma (ATLL) (1), marginal zone leukemia (1), large granular lymphocyte leukemia (2), acute lymphoblastic leukemia (1), and T-cell lymphoma (2). Patients received various alemtuzumab-containing regimens, including single agent (5) or combined with: rituximab (2), pentostatin (6), fludarabine, cyclophosphamide, and rituximab (23), or fractionated cyclophosphamide, vincristine, adriamycin, and dexamethasone (hyper-CVAD) (4). Seven of 20 patients enrolled on the valaciclovir arm experienced CMV reactivation. None of the 20 patients randomized to valganciclovir experienced CMV reactivation (P = .004). In conclusion, this agent was highly effective for prophylaxis of CMV reactivation in patients receiving alemtuzumab. This trial was registered at www.ClinicalTrials.gov as #NCT00562770.<\/jats:p>","DOI":"10.1182\/blood-2007-03-080010","type":"journal-article","created":{"date-parts":[[2007,11,27]],"date-time":"2007-11-27T04:58:57Z","timestamp":1196139537000},"page":"1816-1819","update-policy":"http:\/\/dx.doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":79,"title":["Valganciclovir prevents cytomegalovirus reactivation in patients receiving alemtuzumab-based therapy"],"prefix":"10.1182","volume":"111","author":[{"given":"Susan","family":"O'Brien","sequence":"first","affiliation":[{"name":"Departments ofLeukemia,"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Farhad","family":"Ravandi","sequence":"additional","affiliation":[{"name":"Departments ofLeukemia,"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Todd","family":"Riehl","sequence":"additional","affiliation":[{"name":"Laboratory Medicine, and"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"William","family":"Wierda","sequence":"additional","affiliation":[{"name":"Departments ofLeukemia,"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xuelin","family":"Huang","sequence":"additional","affiliation":[{"name":"Biostatistics and Applied Mathematics, University of Texas M. D. Anderson Cancer Center, Houston"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jeffrey","family":"Tarrand","sequence":"additional","affiliation":[{"name":"Laboratory Medicine, and"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Brandi","family":"O'Neal","sequence":"additional","affiliation":[{"name":"Departments ofLeukemia,"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hagop","family":"Kantarjian","sequence":"additional","affiliation":[{"name":"Departments ofLeukemia,"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"Keating","sequence":"additional","affiliation":[{"name":"Departments ofLeukemia,"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"234","reference":[{"key":"2019111816202909100_B1","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1586\/14737140.5.1.39","article-title":"Alemtuzumab.","volume":"5","author":"Ravandi","year":"2006","journal-title":"Expert Rev Anticancer Ther"},{"key":"2019111816202909100_B2","doi-asserted-by":"crossref","first-page":"3554","DOI":"10.1182\/blood.V99.10.3554","article-title":"Therapeutic role of alemtuzumab (Campath-1H) in patients who have failed fludarabine: results of a large international study.","volume":"99","author":"Keating","year":"2002","journal-title":"Blood"},{"key":"2019111816202909100_B3","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1182\/blood-2002-01-0159","article-title":"Phase II trial of subcutaneous anti-CD52 monoclonal antibody alemtuzumab (Campath-1H) as first-line treatment for patients with B-cell chronic lymphocytic leukemia (B-CLL).","volume":"100","author":"Lundin","year":"2002","journal-title":"Blood"},{"key":"2019111816202909100_B4","doi-asserted-by":"crossref","first-page":"105","DOI":"10.3816\/CLM.2002.n.016","article-title":"Cytomegalovirus viremia during Campath-1H therapy for relapsed and refractory chronic lymphocytic leukemia and prolymphocytic leukemia.","volume":"3","author":"Nguyen","year":"2002","journal-title":"Clin Lymphoma"},{"key":"2019111816202909100_B5","first-page":"1248","article-title":"Cytomegalovirus reactivation during alemtuzumab therapy for chronic lymphocytic leukemia: incidence and treatment with oral ganciclovir.","volume":"89","author":"Laurenti","year":"2004","journal-title":"Haematologica"},{"key":"2019111816202909100_B6","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1002\/cncr.11551","article-title":"Phae II study of alemtuzumab in chronic lymphoproliferative disorders.","volume":"98","author":"Ferrajoli","year":"2003","journal-title":"Cancer"},{"key":"2019111816202909100_B7","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1016\/j.bbmt.2003.10.007","article-title":"Cytomegalovirus prophylaxis and treatment after hematopoietic stem cell transplantation in Canada: a description of current practices and comparison with Centers for Disease Control\/Infectious Diseases Society of America\/American Society for Blood and Marrow Transplantation guideline recommendations.","volume":"10","author":"Fraser","year":"2004","journal-title":"Biol Blood Marrow Transplant"},{"key":"2019111816202909100_B8","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.2165\/00003495-200161080-00013","article-title":"Valganciclovir.","volume":"61","author":"Curran","year":"2001","journal-title":"Drugs"},{"key":"2019111816202909100_B9","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1056\/NEJMoa011759","article-title":"A controlled trial of valganciclovir as induction therapy for cytomegalovirus retinitis.","volume":"346","author":"Martin","year":"2002","journal-title":"N Engl J Med"},{"key":"2019111816202909100_B10","doi-asserted-by":"crossref","first-page":"2971","DOI":"10.1200\/JCO.2005.04.021","article-title":"Eradication of minimal residual disease in B-cell chronic lymphocytic leucemia alter alemtuzumab therapy is associated with prolonged survival.","volume":"23","author":"Moreton","year":"2005","journal-title":"J Clin Oncol"},{"key":"2019111816202909100_B11","doi-asserted-by":"crossref","first-page":"3891","DOI":"10.1200\/JCO.2002.06.119","article-title":"Alemtuzumab in previously treated chronic lymphocytic leucemia patients who also had received fludarabine.","volume":"20","author":"Rai","year":"2002","journal-title":"J Clin Oncol"},{"key":"2019111816202909100_B12","doi-asserted-by":"crossref","first-page":"1567","DOI":"10.1200\/JCO.1997.15.4.1567","article-title":"Phase II multicenter study of human CD52 antibody in previously treated chronic lymphocytic leukemia: European study group of CAMPATH-1H Treatment in chronic lymphocytic leukemia.","volume":"15","author":"Osterborg","year":"1997","journal-title":"J Clin Oncol"},{"key":"2019111816202909100_B13","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1182\/blood-2003-01-0182","article-title":"Expansion of CMV-specific CD8+CD45RA+CD27-T cells in B-cell chronic lymphocytic leukemia.","volume":"102","author":"Mackus","year":"2003","journal-title":"Blood"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/111\/4\/1816\/1220547\/zh800408001816.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/111\/4\/1816\/1220547\/zh800408001816.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,11,18]],"date-time":"2019-11-18T21:20:39Z","timestamp":1574112039000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/111\/4\/1816\/133192\/Valganciclovir-prevents-cytomegalovirus"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,2,15]]},"references-count":13,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2008,2,15]]}},"URL":"https:\/\/doi.org\/10.1182\/blood-2007-03-080010","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2008,2,15]]}}}